Teraderm

Terbinafine Hydrochloride

Method of action: Antifungal Broad Spectrum

Treatment option: Biopsy, Fungal Infection,Fingernail, Athlete'S Foot

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teraderm

Quick Facts

Property	Description
Active ingredient	Terbinafine Hydrochloride
Form	Tablet, Cream, Dusting Powder
Pharmacological class	Antifungal Agent, Allylamine
Common use	Addressing fungal infections
Origin	Synthetic

What Type of Medicine is Teraderm?

Teraderm is a trade name for a synthetic medicine whose active ingredient is Terbinafine Hydrochloride, classified formally as an Antifungal Agent. This substance is specifically grouped within the Allylamine chemical class, clinically recognized for its focused action against common dermatophyte infections.

As a member of the Allylamine class, this medicine represents a focused approach to counteracting fungal overgrowth. This classification establishes its core therapeutic purpose, which is to address the underlying presence of fungi, confirming its role as an anti-infective agent. The general use of Terbinafine is established in this therapeutic area.

Composition and Available Drug Forms

Teraderm is a single-ingredient product whose composition is defined solely by the presence of Terbinafine Hydrochloride, offered in various forms for different routes of consumption. The medicine is prepared for both oral consumption as a Tablet and for topical consumption in external preparations, such as a Cream or a Dusting Powder.

The distinct pharmaceutical preparations are designed to target infections either systemically, via the oral tablet excipients, or locally, using the external cream base or powder base. This dual availability ensures that the active ingredient can be delivered directly to superficial fungal issues or distributed throughout the body to address more pervasive infections, depending on the site and scope of the fungal condition being addressed.

How Does Teraderm Generally Address Fungal Issues?

The general function of Teraderm is to provide a fungicidal action, meaning the medicine actively works to kill the fungal cells responsible for the infection, rather than merely halting their growth. The mechanism relies on interference with the fungus's ability to produce ergosterol, a crucial structural material for its cell membrane.

This interference leads to the structural destruction of the fungal cell, confirming the drug's core benefit: the elimination of the fungal source of the problem. This focused mechanism of effect, which targets the fungal structure, helps to resolve established fungal conditions by removing the pathogen.

Regulatory References

WHO Essential Medicines List

What side effects are possible with Teraderm?

Possible Side Effects and Safety Information

The official safety profile for Teraderm (Terbinafine Hydrochloride) is structured by classifying possible adverse reactions according to the organ system affected and the frequency observed in clinical data.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are classified as Common (occurring in ge 1/100 to <1/10 patients) and involve the gastrointestinal tract, the skin, and the nervous system. These Common effects include headache, gastrointestinal disturbances (such as diarrhea, dyspepsia, and nausea), rash, pruritus, and disturbances in taste or smell.

Less frequently, official regulatory documents note the potential for Rare events (ge 1/10,000 to <1/1,000). The most serious concern in this tier is Hepatotoxicity or Liver Failure, which may occur, and is noted to typically arise within two months of treatment initiation. Cases of Very Rare (<1/10,000) severe reactions include Stevens-Johnson syndrome and other serious skin disorders, as well as severe hematological effects like Neutropenia.

Population-Specific Safety Constraints

The medicine's regulatory label explicitly imposes restrictions on its use for certain individuals. The oral formulation is contraindicated (should not be used) in patients with pre-existing active or chronic liver disease. Additionally, use is not recommended for individuals with severe renal impairment (creatinine clearance le 50 mL/min). The taste and smell disturbances documented in the official profile may be prolonged or permanent in some cases, according to regulatory statements.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Teraderm is a serious, life-threatening, or potentially fatal medical emergency. The critical risks are tied to the uncontrolled release of the active ingredient, resulting in high systemic exposure. Official regulatory information identifies immediate life-threatening events that define an overdose situation.

Documented Overdose Presentations

The most serious manifestations of overdose involve the Central Nervous System (CNS) and the Respiratory System. Presentations may include:

Serious Respiratory Depression: Slowed, shallow, or labored breathing that may progress to respiratory arrest.
Profound Sedation and Coma: Extreme drowsiness, mental impairment, inability to be roused, or loss of consciousness.
Death: Fatal outcomes have been associated with overdose.

Factors Associated with Overdose Risk

The risk of severe overdose is significantly increased by specific exposures and conditions, including:

Accidental Exposure: In children, even small amounts from accidental exposure can result in a fatal overdose and require immediate emergency medical attention.
Misuse or Abuse: Chewing, swallowing, snorting, or injecting the product results in the uncontrolled, rapid release of the active ingredient, posing an extreme risk of life-threatening overdose.
Concomitant Use: Using the product alongside other CNS depressants, such as alcohol or benzodiazepines, can lead to profound sedation, respiratory depression, coma, and death.

Required Emergency Actions

Immediate emergency medical attention must be sought (e.g., calling 911 or emergency services) for any signs of overdose or accidental exposure. Treatment for overdose involves reestablishing a protected airway and providing controlled or assisted ventilation. Administration of an opioid antagonist, such as naloxone, may be required as part of the emergency treatment.

Therapeutic Uses of Teraderm

What Teraderm Treats: Main Uses and Benefits

The primary therapeutic benefit of Teraderm (Terbinafine Hydrochloride) is to provide supportive management against infections caused by pathogenic fungi, particularly dermatophytes. This approach is considered relevant for helping achieve mycological clearance and may assist in easing the associated distressing symptoms.

The medication is commonly used across conditions involving inflammatory or irritative processes. It may also be part of symptomatic management for Tinea infections, including Tinea Corporis (ringworm of the body), Tinea Cruris (jock itch), and Tinea Pedis (athlete's foot), as well as onychomycosis (fungal nail infection).

Supporting Comfort and Functional Stability

This medicine helps address symptom clusters that typically include persistent itching, pronounced redness, and painful cracking of the skin, all of which are symptoms that interfere with daily functioning. The treatment provides support that helps ease the overall symptom burden and may help support the restoration of skin health.

For deep-seated infections of the keratin structures like the nails or scalp, Teraderm is applied when appropriate for these conditions associated with acute or disruptive episodes. This use contributes to improved comfort by addressing structural issues, thereby assists with maintaining functional stability.

Quick Fact: Relevant for Symptoms related to Inflammatory States	Description
Symptom Domain	Symptoms related to inflammatory or irritative states
Primary Benefit	Contributes to easing the overall symptom load
Context of Use	Applied in clinical settings that involve acute or unstable symptom patterns

Regulatory References

NIH DailyMed label for Terbinafine Hydrochloride tablets

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Teraderm — Official Regulatory Information

Regulatory documentation defines strict eligibility rules for oral Teraderm (Terbinafine Hydrochloride) based on patient health status and age, categorizing populations as allowed, not recommended, or strictly contraindicated.

Eligibility Scope

Classification	Population/Condition
Populations for whom use is contraindicated	Chronic or Active Hepatic Disease
	History of Hypersensitivity or Allergic Reaction to Terbinafine
Populations for whom use is not recommended	Patients with Renal Impairment (CrCl le 50 mL/min)
	Pregnant women and breastfeeding mothers
Age-related restrictions	Children younger than 4 years of age (safety/efficacy not established)
Caution required	Patients with pre-existing Psoriasis or Lupus Erythematosus

Eligibility Classifications

Regulatory Status	Definition
Absolute Contraindication	Prohibition of use (e.g., Active Liver Disease, Hypersensitivity)
Not Recommended	Use is discouraged due to limited study data (e.g., Renal Impairment)
Use with Caution	Use requires consideration due to risk of condition exacerbation (e.g., Lupus)

Connection to the overall eligibility profile: Official regulatory documents establish absolute contraindications based on hepatic status and known hypersensitivity to the medicine. Eligibility is further restricted in populations with severe renal impairment or reproductive status (pregnancy/lactation) where use is formally not recommended. These classifications ensure the medicine is reserved for the general adult population and older children where safety and efficacy are established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Teraderm (Terbinafine Hydrochloride oral tablet) has officially documented pharmacokinetic interactions, primarily based on its effect on liver enzymes and the way other substances affect its own clearance.

Pharmacokinetic Interaction Profile

The most significant interaction mechanism is the potent inhibition of the CYP450 2D6 isozyme by Terbinafine. This action formally increases the plasma concentration and reduces the clearance of co-administered medicines that are metabolized primarily by this enzyme, such as Desipramine and certain Beta-blockers or Tricyclic Antidepressants.

Conversely, other medicines alter the plasma exposure of Terbinafine itself. Co-administration with the inhibitor Fluconazole is documented to substantially increase Terbinafine exposure, while the inducer Rifampicin is documented to decrease Terbinafine levels significantly by increasing its clearance.

Interaction Type	Interacting Substance(s)	Official Effect
Inhibitor Effect	Desipramine, Dextromethorphan	Increased exposure/reduced clearance of co-administered drug
Exposure Increase	Fluconazole, Cimetidine	Increased Terbinafine concentration/exposure
Exposure Decrease	Rifampicin, Apalutamide	Reduced Terbinafine concentration/exposure

Interaction-Related Restrictions

The regulatory profile documents a risk of additive hepatotoxicity when oral Terbinafine is co-administered with alcohol. Furthermore, the use of oral Terbinafine is officially restricted for patients with chronic or active liver disease due to the potential for worse hepatic events. The regulatory labeling notes that no mandatory timing separation is required relative to food, as bioavailability is similar regardless of meal intake.

Mechanism of Action

Targeted Inhibition of Fungal Sterol Synthesis

Teraderm's mechanism begins with its active ingredient, Terbinafine Hydrochloride, acting as a specific non-competitive inhibitor of the enzyme squalene epoxidase within the fungal cell. This block directly interrupts the ergosterol biosynthesis pathway, starving the fungus of ergosterol, which is essential for the structural integrity and fluidity of its plasma membrane.

Dual-Action Cellular Cascade

The enzyme inhibition creates a dual cellular effect: the fungal cell is weakened by ergosterol deficiency, and the precursor substance, squalene, accumulates within the cell to toxic levels. This combination of structural failure and internal poisoning results in irreversible cellular damage and membrane lysis. The mechanism exhibits selectivity, focusing its activity on this unique fungal pathway.

Dosage and Administration Information

How to Use Teraderm

The usage of Teraderm (Terbinafine Hydrochloride) depends on the route of administration and the specific formulation selected. The medicine is administered either orally as a 250 mg tablet or granules for systemic effects, or topically as a 1% cream or powder for localized application.

Standard Adult Dosing and Frequency

The standard adult oral dose is fixed at 250 mg once daily. The required treatment duration is defined by the infection site; for instance, administration is specified for 6 weeks for fingernail issues and 12 weeks for toenail issues. Topical application is typically once or twice daily, with durations often ranging from one to two weeks depending on the condition.

Administration Scope	Requirement
Oral Tablet Timing	May be taken with or without food
Oral Granules Timing	Must be taken with food and swallowed immediately, without chewing
Pediatric Dosing	Oral doses are calculated based on the child's body weight (e.g., 125 mg or 187.5 mg tiers)
Topical Principle	Apply to the clean, dry, affected area and surrounding skin
Missed Dose Rule	Take the missed dose as soon as remembered, unless close to the next scheduled dose

Key Procedural Constraints

Instructions include procedural constraints related to proper usage. For systemic use, the oral form is generally not recommended in patients with severely decreased renal function (creatinine clearance leq 50 mL/min) and is contraindicated in patients with active or chronic liver disease. These constraints establish boundaries for the use of the medicine, ensuring its administration is tailored to the patient's physiological state.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Teraderm

This overview summarizes the type of research that has been conducted on Teraderm (Terbinafine Hydrochloride), focusing on the structure of the evidence and what specific outcomes were measured in clinical trials. It does not provide medical advice or recommend treatment.

Evidence for Use in Onychomycosis (Fungal Nail Infection)

Research has examined the systemic (oral tablet) use of Teraderm in the context of fungal infections of the nails, primarily through Randomized Controlled Trials (RCTs) against placebo or other treatments. These studies monitored Mycological Outcome (fungus non-detectability) and Clinical Outcome (residual nail involvement) over several months, reflecting the necessary observation period for the nail. The evidence base is limited regarding outcomes for individuals with mixed fungal infections and for long-term durability of fungal clearance.

Evidence for Superficial Skin Infections

The research for common conditions like Tinea Pedis (athlete's foot) and Tinea Cruris (jock itch) has often involved Randomized, Double-Blind, Vehicle-Controlled Trials. These studies measured outcomes linked to signs and symptoms of inflammatory states, including objective scoring of redness, scaling, and cracking, alongside patient-reported outcomes describing perceived discomfort (e.g., itching). Research highlights changes measured during the study period, with findings related to the detectability of the fungus and the change in these symptoms over short-term time intervals.

Evidence for Tinea Capitis (Scalp Ringworm)

Clinical studies, primarily focused on the Pediatric Population, examined systemic Teraderm in the context of Tinea Capitis. These trials monitored both Mycological Outcome and Clinical Outcome. Data show patterns related to the observed mycological outcome was associated with the specific species of fungus causing the infection. Certainty remains low regarding the full range of outcomes related to all different fungal species.

Long-Term Evidence and Research Gaps

Clinical research includes defined follow-up durations to monitor findings across defined time intervals. However, long-term effects are not fully established beyond the observation periods included in the core clinical trials related to observing mycology findings over many years and the likelihood of recurrence. Data for certain groups remain insufficient, such as older adults or individuals with various comorbidities, meaning results apply primarily to the populations specifically included in the initial evaluation studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Teraderm (FAQ)

Q: Is Teraderm a steroid?

A: Teraderm is not classified as a steroid. Official documents classify its active ingredient, Terbinafine, as an Allylamine Antifungal. This classification establishes its core purpose as an antifungal agent.

Q: How long does it take for Teraderm to start working?

A: The active ingredient is distributed to the skin and nails after the first dose. However, visible clinical improvement, especially for fungal nail infections, can take months. This is because clearance of the infection depends on the slow process of new, healthy nail growth.

Q: Is there a generic version of Teraderm available?

A: Yes, the active ingredient in Teraderm, which is terbinafine hydrochloride, is available in generic forms, according to official drug information.

Q: Can Teraderm cause sun sensitivity?

A: Yes, official warnings indicate that oral Teraderm can make the skin more sensitive to the sun (photosensitivity). The official labeling contains precautions, advising patients that they should minimize exposure to sunlight and artificial light and use protective measures like clothing and sunscreen.

Q: Can Teraderm affect my ability to drive or operate machinery?

A: Regulatory documents note that some people may experience adverse effects such as dizziness and vertigo while taking this medication. The labeling advises caution regarding driving or operating machinery if these side effects occur.

Q: Are there different strengths or doses of the Teraderm patch?

A: The officially approved forms of this medicine are oral tablets, oral granules, and topical 1% cream or powder. The patch form is not listed as an approved dosage form in the full prescribing information.

Q: Can Teraderm interact with over-the-counter pain relievers like ibuprofen?

A: Teraderm has the potential to interact with many different substances and medicines. The official labeling contains a general interaction warning that includes informing the healthcare provider about all prescription and over-the-counter (OTC) products.

Q: Are there any specific foods or drinks to avoid while using Teraderm?

A: Regulatory directions stipulate that oral granules should be mixed with soft, non-acidic food (avoiding fruit-based food). Due to the medicine potentially slowing the breakdown of caffeine, official information suggests caution with caffeine-containing food and drinks.

Q: Is Teraderm used for chronic conditions or only short-term treatment?

A: Oral Teraderm is prescribed for specific, defined treatment durations, such as 6 weeks for fingernail infections and 12 weeks for toenail infections, and is not prescribed for chronic, ongoing use.

Q: Can Teraderm interact with herbal supplements?

A: Yes, official regulatory documents state that Teraderm can interact with various herbal products and supplements. The official labeling advises caution and mentions discussing the use of all supplements with a healthcare provider.

Q: Is it possible to have an allergic reaction to the adhesive in Teraderm?

A: Allergic reactions (hypersensitivity) to any ingredient in the medicine, including both the active ingredient and the inactive components (excipients), are listed as a contraindication. The labeling advises consulting a healthcare provider about known allergies to any ingredients.

Q: Can using Teraderm affect my sleep?

A: Trouble with sleeping, or insomnia, is listed as a potential side effect in regulatory documents. Patients who experience sleep disturbances are advised in the labeling to consult a healthcare provider.

Q: Does Teraderm cause weight gain or weight loss?

A: Weight loss may occur, but it is not a direct side effect. Official warnings note that severe disturbances in taste or smell can sometimes lead to decreased food intake, which may result in unintended weight loss.

Q: Can I apply lotion or oils to the skin where the Teraderm patch goes?

A: Topical forms of Teraderm are directed to be applied to skin that is clean and dry. Since directions stipulate clean and dry skin, the simultaneous use of lotions or oils should be discussed with a healthcare provider.

Q: What is the difference between a patch and a cream for this type of medicine?

A: The approved forms of Teraderm are oral tablets, oral granules, and topical cream or powder. The patch form is not listed in the official product information as an approved dosage form for this medicine.

Q: How does the medicine get into the body from the Teraderm patch?

A: The medicine is fat-soluble (lipophilic), allowing it to distribute effectively into fatty areas of the body. It is distributed to these areas, including the skin, sebum (skin oil), and nails.

Q: What does the patient information leaflet say about stopping Teraderm treatment?

A: Regulatory documents advise patients to immediately report signs of serious side effects (like liver problems, serious skin reactions, or persistent taste/smell changes). The official labeling states that if these reactions occur, the treatment should be discontinued by a healthcare professional.

Q: Does Teraderm affect mood or cause depression?

A: Yes, depressive symptoms are listed as a warning in official documents. The official labeling advises that patients experiencing mood disturbance or depressive symptoms should be reported to a healthcare provider.

Q: Is Teraderm considered a controlled substance?

A: No, Teraderm is not classified as a controlled substance by the US Drug Enforcement Administration (DEA).

Q: Can Teraderm interact with vitamin supplements?

A: Yes, Teraderm can interact with vitamins. The official labeling advises caution and mentions discussing the use of all vitamins, minerals, and supplements with a healthcare provider.

Q: How quickly do side effects from Teraderm usually appear?

A: The onset time is not specified for common side effects like headache or digestive issues. However, the most serious side effect, liver damage, is noted in the regulatory labeling to typically arise within two months of treatment initiation.

Q: Is Teraderm safe for older adults (seniors)?

A: Based on clinical data, no clinically relevant age-dependent changes in the medicine's concentration in the blood have been reported specifically for older adult patients.

How should Teraderm be stored and disposed of?

The storage and disposal of Teraderm (Terbinafine Hydrochloride) must strictly adhere to regulatory labeling requirements.

Official Storage Requirements

Both the tablet and cream formulations must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The tablets must be kept in a tight container and protected from light. For the cream, storage conditions prohibit freezing, and the tube must be kept tightly closed to maintain its integrity.

Stability and Safety

An important stability constraint is that the cream has a limited 28-day shelf life after the tube is first opened. Regardless of the formulation, all products must be kept out of the sight and reach of children.